Log In
Print
BCIQ
Print
Print this Print this
 

Komboglyze, saxagliptin/metformin (Kombiglyze XR)

  Manage Alerts
Collapse Summary General Information
Company AstraZeneca plc
DescriptionFixed-dose combination of Onglyza saxagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, plus metformin
Molecular Target Dipeptidyl peptidase-4 (DPP-4) (CD26)
Mechanism of ActionDipeptidyl peptidase-4 (DPP-4) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type II diabetes; Treat Type II diabetes in combination with insulin
Regulatory Designation

Partner

Otsuka Pharmaceutical Co. Ltd.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today